8F4V

Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
2	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 0.1 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
3	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 100 uM ivermectin, 0.3 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
4	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.55 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
5	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.95 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
6	2D 1H-15N STD TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
7	2D 1H-15N STD TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
8	2D 1H-15N STD TROSY-HSQC	0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
9	2D NOESY	0.20 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
10	2D 1H-15N TROSY-HSQC	0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
11	2D 1H-15N TROSY-HSQC	0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
12	2D 1H-15N TROSY-HSQC	0.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
13	2D 1H-15N TROSY-HSQC	0.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
14	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
15	2D 1H-15N TROSY-HSQC	0.2 % [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
16	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
17	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
18	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
19	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
20	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
21	2D 1H-15N TROSY-HSQC	0.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
22	2D 1H-15N TROSY-HSQC	0.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 240 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
23	2D 1H-15N TROSY-HSQC	0.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
24	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
25	2D 1H-15N TROSY-HSQC	0.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
26	3D TROSY-HNCO	0.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 30 uM PNU, 0.2 % DMSO	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800
27	3D TROSY-HNCO	0.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS	95% H2O/5% D2O	25 mM	4.7	1 atm	318	Bruker AVANCE II 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE II	800

NMR Refinement
Method	Details	Software
na		Rosetta
na

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	1000
Conformers Submitted Total Number	15
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin	3.2	Bruker Biospin
2	processing	NMRPipe	10.9	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	data analysis	Sparky	3.190	Goddard
4	data analysis	NMRFAM-SPARKY	1.470	Lee, Tonelli and Markley
5	structure calculation	CS-ROSETTA	3.17	Shen, Vernon, Baker and Bax
6	structure calculation	Rosetta	3.7	Leaver-Fay, Tyka, Lewis, Lange, Thompson, Jacak, Kaufman, Renfrew, Smith, Sheffler, Davis, Cooper, Treuille, Mandell, Richter, Ban, Fleishman, Corn, Kim, Lyskov, Berrondo, Mentzer, Popovic, Havranek, Karanicolas, Das, Meiler, Kortemme, Gray, Kuhlman, Baker, and Bradley
7	refinement	Rosetta	3.7	Leaver-Fay, Tyka, Lewis, Lange, Thompson, Jacak, Kaufman, Renfrew, Smith, Sheffler, Davis, Cooper, Treuille, Mandell, Richter, Ban, Fleishman, Corn, Kim, Lyskov, Berrondo, Mentzer, Popovic, Havranek, Karanicolas, Das, Meiler, Kortemme, Gray, Kuhlman, Baker, and Bradley
9	refinement	MolProbity		Richardson

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.

Prepare Data

Validate Data

Deposit Data

Help and Resources

8F4V

Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state